Nuvo Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%
News May 14, 2013
Nuvo Research Inc. has announced that the European Patent Office has issued a notice of Intention to Grant a European Patent that provides protection for the Company's PENNSAID® 2% product.
Upon grant by the European Patent Office, the patent can be officially validated in over 37 European countries.
PENNSAID 2% is protected by issued patents in the United States expiring April 21, 2028 and in New Zealand, South Africa and the Russian Federation with an expiration date of October 17, 2027.
Patent applications covering PENNSAID 2% are currently pending in Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and Mexico and have an anticipated expiry date of October 17, 2027.
The Company is currently in discussions with potential marketing partners interested in licensing PENNSAID and/or PENNSAID 2% for Europe, Russia, China, the Middle East, Asia and Australia.
"We are very pleased with the progress we are making to secure worldwide patent protection for our next generation topical NSAID, PENNSAID 2%," said Tina Loucaides, Nuvo's Vice-President and General Counsel.
Loucaides continued, "This expanding patent portfolio supports our efforts to secure international licensing partners for PENNSAID 2% and additional sources of revenue for Nuvo."
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018